Low-Dose Naltrexone as an Adjunct in Chronic Lyme Disease: Mechanisms, Evidence, and Clinical Considerations
Low-Dose Naltrexone as an Adjunct in Chronic Lyme Disease:
Mechanisms, Evidence, and Clinical Considerations
Yoon Hang Kim, MD, MPH
Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician
Introduction
Lyme disease, caused by Borrelia burgdorferi sensu lato (Latin: “in the broad sense,” encompassing the full species complex including B. garinii and B. afzelii), remains one of the most prevalent vector-borne infections in the Northern Hemisphere. While acute infection typically responds to standard antibiotic therapy, an estimated 10–20% of treated patients develop persistent symptoms—fatigue, musculoskeletal pain, cognitive dysfunction, and autonomic disturbance—collectively described as post-treatment Lyme disease syndrome (PTLDS).1,2 For these patients, symptom burden often persists well beyond documented seroconversion and completed antimicrobial courses, raising difficult questions about the relative contributions of ongoing infection, immune dysregulation, and central sensitization.
Low-dose naltrexone (LDN), defined as naltrexone at doses of approximately 0.5–6 mg (far below the 50 mg FDA-approved dose for opioid and alcohol use disorders), has emerged as a mechanistically plausible adjunctive option for managing the inflammatory and neuroimmune symptoms that define chronic and persistent Lyme presentations.3,4 This article reviews the current evidence base, proposed mechanisms of action, practical clinical application, and limitations of LDN in the context of chronic Lyme disease.
Evidence Base and Limitations
It is essential to state clearly at the outset: there are currently no randomized, placebo-controlled clinical trials evaluating LDN specifically in Lyme disease or PTLDS.3,5 The clinical rationale for LDN in Lyme is extrapolated from its growing evidence base in other chronic inflammatory and neuroimmune conditions—most notably fibromyalgia, Crohn’s disease, multiple sclerosis, and complex regional pain syndrome—supplemented by open-label clinician experience and expert opinion within the Lyme-literate community.
A 2026 narrative review published in Advances in Therapy systematically evaluated 105 LDN studies (including 15 RCTs) across pain, autoimmune, gastrointestinal, dermatological, post-infectious, mental health, and oncology indications. The authors concluded that while early uncontrolled studies consistently suggest symptomatic benefit, positive findings have rarely been replicated in placebo-controlled designs, and the overall evidence remains characterized by small sample sizes, subjective outcome measures, and publication bias.6
Within the Lyme-specific literature, the most frequently cited clinical data comes from Dr. Richard Horowitz’s open-label experience with over 1,000 Lyme patients, in which approximately 75% reported reduced fatigue, myalgia, and arthralgia at a mean titrated dose of approximately 4.5 mg.7,8 However, without control groups, blinding, or standardized outcome measures, these data remain hypothesis-generating rather than confirmatory. The LDN Research Trust has featured multiple clinician presentations and patient testimonials describing symptomatic improvement in Lyme disease across their annual conferences, including presentations by Drs. Kent Holtorf and Darin Ingels, though these similarly lack controlled methodology.5,9,10
Clinical implication: LDN for Lyme is best framed as a low-risk, mechanistically plausible adjunct for symptom burden—not as a disease-modifying or antimicrobial therapy. Shared decision-making and transparent discussion of the evidence limitations are essential.
Proposed Mechanisms Relevant to Lyme Disease
LDN’s therapeutic actions at low doses appear to operate through at least three distinct pharmacological pathways, each of which has relevance to the pathophysiology of chronic Lyme symptomatology.4,6,11
1. Toll-Like Receptor 4 (TLR4) Antagonism and Microglial Modulation
Naltrexone acts as a non-stereoselective antagonist at TLR4 on microglial cells in the central nervous system. TLR4 activation drives production of pro-inflammatory cytokines including IL-6, TNF-α, and TGF-β—all of which are elevated in chronic Lyme disease and implicated in neuroinflammation, central sensitization, and pain amplification.4,11,12 By interrupting TLR4-mediated microglial activation, LDN may reduce the sustained neuroinflammatory cascade that contributes to brain fog, fatigue, neuropathic pain, and cognitive dysfunction in PTLDS.
A scoping review published in Pain Medicine (2023) specifically evaluated LDN’s utility for centralized pain conditions and confirmed TLR4-mediated glial cell modulation as the primary mechanistic pathway, with downstream reductions in pro-nociceptive cytokines and improved function, sleep, and quality of life across multiple conditions.13
2. Transient Opioid Receptor Blockade and Endorphin Upregulation
At low doses, naltrexone produces a brief (approximately 6–8 hour) blockade of mu-opioid receptors, which triggers a compensatory rebound upregulation of endogenous opioid peptides (endorphins, enkephalins) and their receptors. This enhanced endorphin tone modulates both pain perception and immune cell function, potentially restoring impaired immune surveillance in the context of chronic infection and immune exhaustion.4,6,14
3. Opioid Growth Factor Receptor (OGFr) Modulation
More recently, a third pathway has been proposed involving temporary antagonism of the opioid growth factor receptor (OGFr), leading to compensatory upregulation of opioid growth factor (OGF, met-enkephalin) and its receptor. This axis regulates cellular proliferation and immune modulation through mechanisms partially independent of classical opioid signaling.6
Integrative relevance: For clients with persistent Lyme symptoms overlapping with mast cell activation syndrome (MCAS), central sensitization, or post-infectious autoimmunity, LDN’s multi-target anti-inflammatory and immunomodulatory profile is particularly attractive as it addresses several converging pathophysiological pathways simultaneously.
Clinical Role in Lyme Disease Protocols
Lyme-literate clinicians who incorporate LDN generally position it as one component of a comprehensive, multimodal treatment plan that continues to address active infection (antibiotics or herbal antimicrobials), co-infections (Babesia, Bartonella, Ehrlichia), and comorbid drivers such as MCAS, mold illness, dysautonomia, and hormonal imbalances.3,8,14 LDN is not a substitute for antimicrobial therapy when active infection is suspected or documented.
In clinical practice, LDN is most commonly prescribed for the following symptom domains in chronic/persistent Lyme:
Dr. Marty Ross, MD, a Seattle-based clinician with extensive Lyme experience, has noted that while no formal studies exist on LDN in Lyme specifically, the medication’s ability to modulate TLR-mediated nerve pain, enhance endorphin function, and reduce systemic inflammation makes it a logical fit for the multi-system symptom profiles seen in chronic tick-borne illness.14
Dosing, Titration, and Administration
Because naltrexone is commercially available only as a 50 mg tablet, LDN must be compounded to the appropriate low-dose range. Most compounding pharmacies offer capsules or liquid formulations.7,8
Individualization is important. Some clients experience optimal symptom control at sub-maximal doses (e.g., 2–3 mg) and should not be routinely pushed to the 4.5 mg target if they are responding well at a lower level. Town & Country Compounding has developed a patient-specific titration kit starting at 0.5 mg with weekly 0.5 mg increases, emphasizing the value of the physician–patient–pharmacy triad in LDN management.7
Safety, Tolerability, and Precautions
LDN has a well-established safety profile derived from naltrexone’s decades of clinical use in addiction medicine. At low doses, it is generally well tolerated. The most commonly reported adverse effects include vivid dreams, initial insomnia, headache, transient nausea, mild fatigue, and restlessness—most of which are self-limiting and can be mitigated by slower titration or shifting the dose to the morning if sleep disruption predominates.3,4,8
Additional clinical monitoring considerations include periodic assessment of liver function (given naltrexone’s hepatic metabolism at higher doses), and counseling regarding the off-label nature of LDN use for Lyme and related conditions.3,4
Practical Clinical Considerations
For clients presenting with persistent post-treatment Lyme symptoms and coexisting immune dysregulation—particularly those with overlapping MCAS, mold illness, autoimmunity, or a CFS-like phenotype—LDN is mechanistically attractive as an adjunct that simultaneously targets central sensitization, microglial activation, and cytokine-driven inflammation.3,8,14
Given the absence of high-quality Lyme-specific RCTs, shared decision-making is paramount. LDN should be positioned as a low-cost, low-risk therapeutic trial to reduce symptom burden while the clinician continues to evaluate for ongoing infection, co-infections, dysautonomia, environmental drivers, and metabolic contributors. Its favorable safety profile, low monthly cost ($30–60 from most compounding pharmacies), and potential for meaningful symptom relief make it a reasonable addition to comprehensive chronic Lyme protocols when used with appropriate expectations and monitoring.
Importantly, LDN is compatible with most antibiotics commonly used in Lyme treatment (doxycycline, amoxicillin, azithromycin) and with antimalarials used for Babesia co-infection. The primary drug interaction of concern remains concurrent opioid use.3,8
Conclusion
Low-dose naltrexone represents a mechanistically rational, well-tolerated, and affordable adjunctive option for managing the persistent inflammatory and neuroimmune symptoms that characterize chronic Lyme disease and PTLDS. Its multi-target pharmacology—spanning TLR4 antagonism, microglial modulation, endorphin upregulation, and OGFr modulation—addresses several convergent pathways implicated in post-infectious symptom persistence.
However, the evidence base remains limited to mechanistic extrapolation, open-label clinical experience, and expert consensus. Rigorous, adequately powered randomized controlled trials in Lyme and PTLDS populations are critically needed to move LDN from a plausible adjunct to an evidence-based recommendation. Until such data are available, LDN should be offered within the framework of informed consent, shared decision-making, and comprehensive multimodal care.
References
1. Aucott JN, Soloski MJ, Rebman AW, et al. CCL19 as a chemokine risk factor for post-treatment Lyme disease syndrome: a prospective clinical cohort study. Clin Vaccine Immunol. 2016;23(9):757–766.
2. Rebman AW, Aucott JN. Post-treatment Lyme disease as a model for persistent symptoms in Lyme disease. Front Med. 2020;7:57.
3. Cameron D. Low-dose naltrexone for Lyme disease. danielcameronmd.com. Accessed June 2026. https://danielcameronmd.com/low-dose-naltrexone-lyme/
4. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. PMC3962576.
5. LDN Research Trust. Lyme disease and low dose naltrexone (LDN). ldnresearchtrust.org. Accessed June 2026. https://ldnresearchtrust.org/lyme-disease-and-low-dose-naltrexone-ldn
6. Low-dose naltrexone: what is the evidence? A narrative review. Adv Ther. 2026. https://link.springer.com/article/10.1007/s12325-026-03612-5
7. Town & Country Compounding. Lyme disease & low dose naltrexone (LDN). tccompound.com. Accessed June 2026. https://tccompound.com/blogs/health-hub/new-advancements-in-lyme-disease-options
8. Maderis T. Low dose naltrexone (LDN) for Lyme disease. drtoddmaderis.com. 2020; updated 2023. https://drtoddmaderis.com/low-dose-naltrexone-ldn-for-lyme-disease
9. Holtorf K. Immune dysfunction and chronic Lyme disease. Presentation at LDN Research Trust 2017 Conference. https://ldnresearchtrust.org/dr-kent-holtorf-presentation-immune-dysfunction-ldn-2017-conference
10. Ingels D. Lyme disease. Presentation at LDN Research Trust 2021 Conference. https://ldnresearchtrust.org/lyme-disease-darin-ingels-nd-2021-conference-ldn-low-dose-naltrexone
11. Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2):16.
12. Horowitz RI. Precision medicine: the role of the MSIDS model in defining, diagnosing, and treating chronic Lyme disease/post treatment Lyme disease syndrome and other chronic illness: part 2. Healthcare. 2018;6(4):129. PMC6316761.
13. Diasso GDH, et al. Low-dose naltrexone’s utility for non-cancer centralized pain conditions: a scoping review. Pain Medicine. 2023;24(11):1270–1284.
14. Ross M. Low dose naltrexone (LDN) & Lyme. treatlyme.com. Updated March 2025. https://treatlyme.com/guide/low-dose-naltexone-lyme-disease/
15. LDN Research Trust. Is low dose naltrexone (LDN) effective for Lyme disease? ldnresearchtrust.org. October 2023. https://ldnresearchtrust.org/low-dose-naltrexone-ldn-effective-lyme-disease
About Dr. Kim
Dr. Yoon Hang “John” Kim is a board-certified Preventive Medicine physician with over 20 years of clinical experience in integrative and functional medicine. A graduate of the University of Arizona’s Integrative Medicine Fellowship under Dr. Andrew Weil (Osher Fellow), he also holds certification in UCLA Medical Acupuncture and advanced training in integrative and holistic medicine.
Dr. Kim specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of three books and over 20 peer-reviewed and clinical articles on integrative medicine topics.
Professional: www.yoonhangkim.com
Clinical: www.directintegrativecare.com
